Chapel Hill-based Target PharmaSolutions is wrapping up 2018 with a pair of new partnerships, further pushing the fast-developing company toward what its CEO says will be a better 2019.
This month, the clinical data company announced strategic partnerships with Gilead Sciences (Nasdaq: GILD) and Bristol-Myers Squibb (NYSE: BMY) to expand its research work.
Gilead is the first partner to join the company’s Target-Hepatitis B study. It will also be entering the Target-NASH (nonalcoholic fatty…
